Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive

Clinical Pharmacokinetics

Volumn 43, Issue 10, 2004, Pages 673-684

  Yu, Zhiling ^a   Yu, Dale ^a   Walker, Patricia S ^a   Tang Liu, Diane D S ^a  

^a ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; MESTRANOL PLUS NORETHISTERONE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; TAZAROTENE;

ACNE; ADULT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRY SKIN; ERYTHEMA; FEMALE; HEADACHE; HEMOCONCENTRATION; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEDICAL ASSESSMENT; MENSTRUAL CYCLE; MICROPARTICLE ENZYME IMMUNOASSAY; NAUSEA; NORMAL HUMAN; PARAMETER; PATIENT SELECTION; PRIORITY JOURNAL; PRURITUS; RADIOIMMUNOASSAY; RASH; SIDE EFFECT; SOLID PHASE MICROEXTRACTION;

ADULT; AREA UNDER CURVE; CONTRACEPTIVES, ORAL, SYNTHETIC; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; DRUG INTERACTIONS; ETHINYL ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; MIDDLE AGED; NICOTINIC ACIDS; NORETHINDRONE; PROGESTERONE;

EID: 3342880302     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200443100-00003     Document Type: Article

References (40)

1. Tang-Liu DD, Matsumoto RM, Usansky JI. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet 1999; 37: 273-87
2. Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997; 37: 85-92
3. Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis 1999; 63: 349-54
4. Allergan PKDM Study Report PK-99-089. Evaluation of AGN 190299 as an inhibitor of human P450 enzymes. Irvine (CA): Allergan, 1999. (Data on file)
5. Yu Z, Sefton J, Lew-Kaya DA, et al. Pharmacokinetics of tazarotene cream 0.1% after a single dose and after repeat topical applications at clinical or exaggerated application rates in patients with acne vulgaris or photodamaged skin. Clin Pharmacokinet 2003; 42 (10): 921-9
6. Allergan PKDM Study Report PK-99-004. A single-center, open-label, increasing-dose study to assess the safety and pharmacokinetics of single and multiple (5-days) doses of oral tazarotene administered to healthy subjects. Irvine (CA): Allergan, 1999. (Data on file)
7. Allergan PKDM Study Report PK-01-063. A pharmacokinetic report of tazarotene and tazarotenic acid in human plasma for studies 190168-511P-02 and 190168-512P-00 titled "An open phase I dose escalation study of the safety and pharmacokinetics of oral tazarotene in patients with refractory cancer". Irvine (CA): Allergan, 2001. (Data on file)
8. Allergan PKDM Study Report PK-01-088. A pharmacokinetic report of tazarotene and its metabolite tazarotenic acid in human plasma for study 190168-039P titled "A single-center, open-label, randomized, parallel group, dose proportionality study to assess the safety and pharmacokinetics of 3mg, 6.3mg, 9mg, and 12mg oral tazarotene administered once daily to healthy subjects after a single dose and after a 7 day treatment period". Irvine (CA): Allergan, 2001. (Data on file)
9. Chandraratna RAS. Tazarotene: first of a new generation of receptor-selective retinoids. Br J Dermatol 1996; 135: 18-25
10. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med 1985; 313: 837-41
11. Nau H. Embryotoxicity and teratogenicity of topical retinoic acid. Skin Pharmacol 1993; 6 Suppl. 3: 35-44
12. Nulman I, Berkovitch M, Klein J, et al. Steady-state pharmacokinetics of isotretinoin and its 4-oxo metabolite: implications for fetal safety. J Clin Pharmacol 1998; 38: 926-30
13. Lehucher Ceyrac D, Serfaty D, Lefrancq H. Retinoids and contraception. Dermatology 1992; 184: 161-70
14. Geiger JM, Baudin M, Saurat J-H. Teratogenic risk with etretinate and acitretin treatment. Dermatology 1994; 189: 109-16
15. Holmes SC, Bankowska U, Mackie RM. The prescription of isotretinoin to women: is every precaution taken? Br J Dermatol 1998; 138: 450-5
16. Atanackovic G, Koren G. Young women taking isotretinoin still conceive: role of physicians in preventing disaster. Can Fam Physician 1999; 45: 289-92
17. Trussell J. Contraceptive efficacy. Arch Dermatol 1995; 131: 1064-8
18. Allergan PKDM Study Report PK-95-048. Pharmacokinetics of AGN 190168 following single dose and multiple dose topical administration of 0.1 % gel or 0.05% gel to subjects with stable plaque psoriasis. Irvine (CA): Allergan, 1995. (Data on file)
19. Allergan PKDM Study Report PK-99-095. A single-center, open-label, pharmacokinetic-pharmacodynamic study of the drug-drug area under the plasma concentration-time curve from zero to 24 hours interaction of oral tazarotene and Ortho-Novum® 1/35 oral contraceptive in healthy female volunteers. Irvine (CA): Allergan, 1999. (Data on file)
20. Allergan PKDM Study Report PK-01-143. Quantitation of AGN 190168 and its metabolite, AGN 190299, in human plasma for Allergan protocol number 190168-042P titled "A single-center, open-label study of the effect of oral tazarotene on the pharmacokinetics and pharmacodynamics of the components of Ortho Novum® 1/35 oral contraceptive in healthy female volunteers". Irvine (CA): Allergan, 2001. (Data on file)
21. Allergan PKDM Study Report PK-99-075. GC/MS analysis of 17α-ethinyl estradiol and norethindrone in human plasma for Allergan protocol number 190168-018P titled "A single-center, open-label, pharmacokinetic- pharmacodynamic study of the drug-drug interaction of oral tazarotene and OrthoNovum® 1/35 oral contraceptive in healthy female volunteers". Irvine (CA): Allergan, 1999. (Data on file)
22. Allergan PKDM Study Report PK-01-145. GC/MS analysis of ethinyl estradiol and norethindrone in EDTA human plasma for Allergan protocol number 190168-042P titled "A single-center, open-label study of the effect of oral tazarotene on the pharmacokinetics and pharmacodynamics of the components of Ortho Novum® 1/35 oral contraceptive in healthy female volunteers". Irvine (CA): Allergan, 2001. (Data on file)
23. Allergan PKDM Study Report PK-99-107. MEIA analysis of follicle stimulating hormone and luteinizing hormone in human serum. Irvine (CA): Allergan, 1999. (Data on file)
24. Allergan PKDM Study Report PK-01-096. Quantitation of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and progesterone for Allergan protocol number 190168-042p titled "A single-center, open-label study of the effect of oral tazarotene on the pharmacokinetics and pharmacodynamics of the components of Ortho Novum® 1/35 oral contraceptive in healthy female volunteers". Irvine (CA): Allergan, 2001. (Data on file)
25. Grooowski AM, Landau-Levine M. Reproductive endocrine function. In: Burtis CA, Ashwood ER, editors. Tietz textbook of clinical chemistry. 3rd ed. Philadelphia (PA): WB Saunders Co, 1999: 1601-41
26. Kuhnz W, Back D, Power J, et al. Concentration of ethinyl estradiol in the serum of 31 young women following a treatment period of 3 months with two low-dose oral contraceptives in an intraindividual cross-over design. Hormone Res 1992; 36: 63-9
27. LeBel M, Masson E, Guilbert E, et al. Effects of rifabutin and rifampicin on the pharmacokinetics of ethinyl estradiol and norethindrone. J Clin Pharmacol 1998; 38: 1042-50
28. Wilbur K, Ensom MH. Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants. Clin Pharmacokinet 2000; 38 (4): 355-65
29. Allergan PKDM Study Report PK-94-091. Effect of AGN 190168 on hepatic drug metabolizing enzymes in Sprague-Dawley rats. Irvine (CA): Allergan, 1994. (Data on file)
30. Allergan PKDM Study Report PK-99-059. Evaluation of AGN 190299 as an inhibitor of human P450 enzymes. Irvine (CA): Allergan, 1999. (Data on file)
31. Wiegand UW, Chou RC. Pharmacokinetics of oral isotretinoin. J Am Acad Dermatol 1998; 39: S8-12
32. Larsen FG, Nielsen-Kudsk F, Jakobsen P, et al. Pharmacokinetics and therapeutic efficacy of retinoids in skin diseases. Clin Pharmacokinet 1992; 23 (1): 42-61
33. Allen JG, Bloxham DP. The pharmacology and pharmacokinetics of the retinoids. Pharmacol Ther 1989; 40 (1): 1-27
34. Pilkington T, Brogden RN. Acitretin: a review of its pharmacology and therapeutic use. Drugs 1992; 43 (4): 597-627
35. Massarella J, Vane F, Buggé C, et al. Etretinate kinetics during chronic dosing in severe psoriasis. Clin Pharmacol Ther 1985; 37: 439-46
36. Sturkenboon MCJM, de Jong-Van den Berg LTW, van Voorst-Vader PC, et al. Inability to detect plasma etretinate and acitretin is a poor predictor of the absence of these teratogens in tissue after stopping acitretin treatment. Br J Clin Pharmacol 1994; 38: 229-35
37. Larsen FG, Jakobsen P, Knudsen J, et al. Conversion of acitretin into etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 1993; 100: 623-7
38. Lambert WE, Meyer E, De Leenheer AP, et al. Pharmacokinetics and drug interactions of etretinate and acitretin. J Am Acad Dermatol 1992; 27: S19-22
39. Meyer E, De Bersaques J, Lambert WE, et al. Skin, adipose tissue and plasma levels of acitretin with rare occurrence of esterified acitretin during long-term treatment. Acta Derm Venereol (Stockh) 1993; 73: 113-5
40. Physicians' Desk Reference: electronic edition [online]. Available from URL: http://www.pdr.net/pdrnet/librarian [Accessed 2004 Jun 24]